Payment overview · 2025
General Payments
$1,678.39
75 reported records · 23 companies
Healthcare provider profile · identity verified
Charles B Stone, MD
Allopathic & Osteopathic Physicians|General Practice · HOLLYWOOD, FL · NPI 1881700615
Verified facts
What the public records show
CMS Open Payments records show Charles B Stone, MD received $1,678.39 in general payments during 2025 across 75 reported records.
PFIZER INC. accounted for 12.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Entresto, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Shingrix, Trelegy Ellipta, Viberzi, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Viberzi by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Descovy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 476 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $206.49 | 12.3% | 10 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $198.88 | 11.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $170.45 | 10.2% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $134.53 | 8.0% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $120.55 | 7.2% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $116.93 | 7.0% | 6 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $89.43 | 5.3% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $71.70 | 4.3% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.55 | 3.6% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $60.03 | 3.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $59.83 | 3.6% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.12 | 3.0% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $49.31 | 2.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.33 | 2.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $45.75 | 2.7% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.02 | 2.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.50 | 2.2% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $24.44 | 1.5% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.45 | 1.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.25 | 1.3% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.30 | 1.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.84 | 1.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.71 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,678.39 | 75 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $198.88 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $126.08 | 6 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $106.19 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $100.17 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $94.78 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $89.49 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $89.49 | 5 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $89.43 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $86.71 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $80.41 | 4 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $66.86 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $60.55 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.55 | 4 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $60.42 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $59.83 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $51.12 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $45.75 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.37 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $40.51 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.46 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.46 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.46 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $39.02 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $37.20 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $36.50 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $36.50 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $36.50 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.19 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.19 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.34 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $27.44 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $25.77 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $22.83 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 11 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 476 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 45 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 61 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 80 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 60 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 169 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 224 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 14 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 137 | exact normalized | Medicare Part D |
| VIBERZI viberzi |
2025 | Viberzi | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
83 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
37 | 24 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
57 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 23 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
137 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
169 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
224 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
476 | 86 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2196 | 551 |
| Amlodipine Besylate | Amlodipine Besylate | 1131 | 299 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1094 | 267 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 930 | 289 |
| Lisinopril | Lisinopril | 865 | 214 |
| Losartan Potassium | Losartan Potassium | 646 | 194 |
| Omeprazole | Omeprazole | 619 | 166 |
| Metformin Hcl | Metformin Hcl | 574 | 162 |
| Eliquis | Apixaban | 476 | 86 |
| Gabapentin | Gabapentin | 438 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 417 | 110 |
| Tamsulosin Hcl | Tamsulosin Hcl | 415 | 99 |
| Simvastatin | Simvastatin | 401 | 102 |
| Donepezil Hcl | Donepezil Hcl | 396 | 74 |
| Alprazolam | Alprazolam | 372 | 111 |
| Furosemide | Furosemide | 361 | 103 |
| Carvedilol | Carvedilol | 353 | 87 |
| Escitalopram Oxalate | Escitalopram Oxalate | 320 | 105 |
| Metoprolol Tartrate | Metoprolol Tartrate | 320 | 85 |
| Famotidine | Famotidine | 310 | 99 |
| Montelukast Sodium | Montelukast Sodium | 307 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 295 | 88 |
| Nifedipine Er | Nifedipine | 291 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 285 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 249 | 80 |
| Ezetimibe | Ezetimibe | 241 | 73 |
| Trazodone Hcl | Trazodone Hcl | 236 | 64 |
| Ozempic | Semaglutide | 224 | 43 |
| Sertraline Hcl | Sertraline Hcl | 210 | 47 |
| Doxazosin Mesylate | Doxazosin Mesylate | 202 | 56 |
| Mirtazapine | Mirtazapine | 201 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 198 | 44 |
| Lorazepam | Lorazepam | 196 | 36 |
| Memantine Hcl | Memantine Hcl | 191 | 49 |
| Finasteride | Finasteride | 177 | 43 |
| Allopurinol | Allopurinol | 175 | 53 |
| Potassium Chloride | Potassium Chloride | 173 | 42 |
| Mounjaro | Tirzepatide | 169 | 39 |
| Prednisone | Prednisone | 158 | 106 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 56 |
| Alendronate Sodium | Alendronate Sodium | 152 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 55 |
| Xarelto | Rivaroxaban | 145 | 32 |
| Atenolol | Atenolol | 144 | 34 |
| Levetiracetam | Levetiracetam | 144 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 137 | 37 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 130 | 101 |
| Doxycycline Hyclate | Doxycycline Hyclate | 129 | 111 |
| Latanoprost | Latanoprost | 128 | 23 |
| Tramadol Hcl | Tramadol Hcl | 123 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 37 |
| Spironolactone | Spironolactone | 122 | 37 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 117 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 32 |
| Temazepam | Temazepam | 108 | 18 |
| Januvia | Sitagliptin Phosphate | 100 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 98 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 24 |
| Clonazepam | Clonazepam | 89 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 87 | 16 |
| Glimepiride | Glimepiride | 84 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 17 |
| Meloxicam | Meloxicam | 83 | 37 |
| Synthroid | Levothyroxine Sodium | 83 | 27 |
| Lactulose | Lactulose | 81 | 19 |
| Jardiance | Empagliflozin | 80 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 80 | 36 |
| Labetalol Hcl | Labetalol Hcl | 78 | 18 |
| Metformin Hcl Er | Metformin Hcl | 76 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 75 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 74 | 16 |
| Valsartan | Valsartan | 73 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 23 |
| Ipratropium Bromide | Ipratropium Bromide | 68 | 27 |
| Baclofen | Baclofen | 63 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 19 |
| Warfarin Sodium | Warfarin Sodium | 63 | 12 |
| Farxiga | Dapagliflozin Propanediol | 61 | 20 |
| Ibuprofen | Ibuprofen | 61 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 17 |
| Linzess | Linaclotide | 60 | 15 |
| Midodrine Hcl | Midodrine Hcl | 60 | suppressed |
| Digoxin | Digoxin | 59 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 59 | 12 |
| Lovastatin | Lovastatin | 57 | suppressed |
| Myrbetriq | Mirabegron | 57 | 20 |
| Azithromycin | Azithromycin | 55 | 41 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 55 | 39 |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | 16 |
| Diazepam | Diazepam | 53 | 19 |
| Klor-Con 10 | Potassium Chloride | 52 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 52 | 22 |
| Celecoxib | Celecoxib | 50 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 50 | 14 |
| Pregabalin | Pregabalin | 50 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 33 |
| Azelastine Hcl | Azelastine Hcl | 49 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 37 |
| Glipizide Er | Glipizide | 46 | 14 |
| Levofloxacin | Levofloxacin | 46 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 13 |
| Tradjenta | Linagliptin | 46 | suppressed |
| Entresto | Sacubitril/Valsartan | 45 | 13 |
| Mupirocin | Mupirocin | 45 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 12 |
| Propranolol Hcl | Propranolol Hcl | 44 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 23 |
| Benazepril Hcl | Benazepril Hcl | 43 | 11 |
| Clonidine Hcl | Clonidine Hcl | 42 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 14 |
| Bumetanide | Bumetanide | 41 | 12 |
| Glipizide | Glipizide | 40 | 16 |
| Meclizine Hcl | Meclizine Hcl | 40 | 20 |
| Orencia | Abatacept | 40 | suppressed |
| Ramipril | Ramipril | 40 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 38 | 33 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 16 |
| Prolia | Denosumab | 37 | 24 |
| Tivicay | Dolutegravir Sodium | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Folic Acid | Folic Acid | 36 | 14 |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Fluconazole | Fluconazole | 35 | 23 |
| Repatha Syringe | Evolocumab | 34 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 17 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 33 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | 11 |
| Methylprednisolone | Methylprednisolone | 33 | 21 |
| Nystatin | Nystatin | 33 | 19 |
| Telmisartan | Telmisartan | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 32 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 13 |
| Viberzi | Eluxadoline | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 12 |
| Lacosamide | Lacosamide | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | 12 |
| Bupropion Xl | Bupropion Hcl | 30 | 14 |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 23 |
| Timolol Maleate | Timolol Maleate | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | 11 |
| Acyclovir | Acyclovir | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 23 | 15 |
| Wegovy | Semaglutide | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Budesonide | Budesonide | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Ciclopirox | Ciclopirox | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Rivastigmine | Rivastigmine | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Calcium Acetate | Calcium Acetate | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Multaq | Dronedarone Hcl | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 17 |
| Praluent Pen | Alirocumab | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Alphagan P | Brimonidine Tartrate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Rezvoglar Kwikpen | Insulin Glargine-Aglr | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 13 |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Epogen | Epoetin Alfa | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,678.39 · 75 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, Arikayce, Brinsupri, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, FARXIGA, FREESTYLE LIBRE, GEMTESA, INSPIRE, JARDIANCE, KEVEYIS, KISUNLA, LEQVIO, LINZESS, Leqembi, LifeVest, MOUNJARO, NEXLETOL, NURTEC ODT, ONPATTRO, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VIBERZI, VYNDAQEL, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error